Sunshine Biopharma, Inc. (SBFM) has released an update.
Sunshine Biopharma Inc. experienced a significant year with a 14% average quarterly sales growth in 2023, reaching $24.09 million, partly due to the acquisition of Nora Pharma. The company also decreased its loss per share from $1.76 to $0.19 and furthered the development of two proprietary drugs. Despite challenges, like halting studies on an anticancer compound, Sunshine Biopharma is optimistic about continuing growth and profitability.
For further insights into SBFM stock, check out TipRanks’ Stock Analysis page.
